1. Home
  2. ICFI vs NTLA Comparison

ICFI vs NTLA Comparison

Compare ICFI & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ICF International Inc.

ICFI

ICF International Inc.

HOLD

Current Price

$87.07

Market Cap

1.8B

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$12.28

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICFI
NTLA
Founded
1969
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
2006
2016

Fundamental Metrics

Financial Performance
Metric
ICFI
NTLA
Price
$87.07
$12.28
Analyst Decision
Buy
Buy
Analyst Count
4
18
Target Price
$99.25
$18.34
AVG Volume (30 Days)
129.7K
6.9M
Earning Date
02-26-2026
02-26-2026
Dividend Yield
0.63%
N/A
EPS Growth
N/A
N/A
EPS
5.30
N/A
Revenue
$1,925,502,000.00
$57,528,000.00
Revenue This Year
N/A
$1.71
Revenue Next Year
$2.52
N/A
P/E Ratio
$16.66
N/A
Revenue Growth
N/A
33.52
52 Week Low
$72.03
$5.90
52 Week High
$117.71
$28.25

Technical Indicators

Market Signals
Indicator
ICFI
NTLA
Relative Strength Index (RSI) 45.22 46.63
Support Level $87.93 $10.94
Resistance Level $94.40 $13.76
Average True Range (ATR) 2.72 1.31
MACD -0.99 -0.37
Stochastic Oscillator 13.10 12.75

Price Performance

Historical Comparison
ICFI
NTLA

About ICFI ICF International Inc.

ICF International Inc provides professional services and technology-based solutions to government and commercial clients, including management, marketing, technology, and policy consulting and implementation services. Its services support clients that operate in four key markets that include Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs and Security and Other Civilian & Commercial. The Company's majority clients are United States federal government departments and agencies. It operates in a single segment, which is providing professional services.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: